After a New Drug Application (NDA) is received by the agency, it undergoes a technical screening generally referred to as a
completeness review. This evaluation ensures that sufficient data and information have been submitted in each area to justify
"filing" the application--that is, justifying initiating CDER's formal review of the NDA.